Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 13008 [2015-05577]
Download as PDF
<![CDATA[
13008
Federal Register / Vol. 80, No. 48 / Thursday, March 12, 2015 / Notices
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
or other forms of information
technology to minimize the information
collection burden.
Terry S. Clark,
Deputy Information Collection Clearance
Officer.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2015–05619 Filed 3–11–15; 8:45 am]
BILLING CODE 4150–28–P
[FR Doc. 2015–05577 Filed 3–11–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Food and Drug Administration
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
[Docket No. FDA–2015–N–0001]
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting for the initial
review of applications in response to
[(FOA) GH15–001, Conducting Public
Health Research in Kenya, Funding
Opportunity Announcement.
Time and Date: 12:00 p.m.—5:00 p.m.,
April 1, 2015 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters for Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Conducting Public Health
Research in Kenya, FOA GH15–001’’.
Contact Person for More Information:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road, NE.,
Mailstop D–69, Atlanta, Georgia 30033,
Telephone: (404) 639–4796.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
2015 Parenteral Drug Association/Food
and Drug Administration Joint
Conference
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public conference.
The Food and Drug Administration
(FDA), is announcing a public
conference, to be held in co-sponsorship
with the Parenteral Drug Association
(PDA), entitled ‘‘Mission Possible:
Patient-Focused Manufacturing,
Quality, and Regulatory Solutions.’’ The
conference will cover current issues
affecting the industry as well as explore
strategies to facilitate the development
and continuous improvement of safe
and effective medical products. The
conference establishes a unique forum
to discuss the foundations, emerging
technologies, and innovations in
regulatory science, as well as the current
quality and compliance areas of
concerns. Meeting participants will hear
from FDA and industry speakers about
the requirements and best practices to
consider while implementing robust
quality systems in order to deliver the
best quality product.
Date and Time: The public conference
will be held on September 28, 2015,
from 7 a.m. to 7:30 p.m.; September 29,
2015, from 7 a.m. to 9:30 p.m.; and
September 30, 2015, from 7 a.m. to
12:30 p.m.
Location: The public conference will
be held at the Renaissance Washington
Hotel, 999 Ninth Street NW.,
Washington, DC 20001, 202–898–9000,
FAX: 202–289–0947.
Contact: Wanda Neal, Parenteral Drug
Association, PDA Global Headquarters,
Bethesda Towers, 4350 East West Hwy.,
Suite 150, Bethesda, MD 20814, 301–
656–5900, ext. 111, FAX: 301–986–
1093, email: info@pda.org; or Ken
Nolan, Office of Communications, Food
and Drug Administration, 10903 New
Hampshire Ave., Silver Spring, MD
20993, 301–796–8629, email:
kenneth.nolan@fda.hhs.gov.
Accommodations: Attendees are
responsible for their own
accommodations. To make reservations,
contact the Renaissance Washington
Hotel (see Location) and reference ‘‘the
2015 PDA/FDA Joint Regulatory
Conference’’ to receive the PDA group
rate. Room rates are: Single: $305 plus
14.5 percent State and local taxes.
Requests will be processed on a firstcome, first-served basis.
Registration: Attendees are
encouraged to register at their earliest
convenience. The PDA registration fees
cover the cost of facilities, materials,
and refreshments. Seats are limited;
please submit your registration as soon
as possible. Conference space will be
filled in order of receipt of registration.
Those accepted for the conference will
receive confirmation. Registration will
close after the conference is filled.
Onsite registration will be available on
a space available basis beginning at 1
p.m. on September 27, 2015, and at 7
a.m. from September 28 through 30,
2015. The cost of registration is as
follows:
COST OF REGISTRATION
Before July
19, 2015
Affiliation
July 19–
August 18,
2015
After August
18, 2015
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Premier Package (Includes Conference and Workshop Registration)
Member ....................................................................................................................................................
Nonmember .............................................................................................................................................
$3,240
3,599
$3,490
3,849
$3,740
4,099
1,895
2,154
700
800
700
800
2,095
2,354
700
800
700
800
2,295
2,554
700
800
700
800
Conference Only
Member ....................................................................................................................................................
Nonmember .............................................................................................................................................
Government/Health Authority Member ....................................................................................................
Government/Health Authority Nonmember * ...........................................................................................
Academic Member ...................................................................................................................................
Academic Nonmember * ..........................................................................................................................
VerDate Sep<11>2014
17:40 Mar 11, 2015
Jkt 235001
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
E:\FR\FM\12MRN1.SGM
12MRN1
]]>Agencies
[Federal Register Volume 80, Number 48 (Thursday, March 12, 2015)]
[Notices]
[Page 13008]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-05577]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
In accordance with Section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces a meeting for the initial review of
applications in response to [(FOA) GH15-001, Conducting Public Health
Research in Kenya, Funding Opportunity Announcement.
Time and Date: 12:00 p.m.--5:00 p.m., April 1, 2015 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the public in accordance
with provisions set forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director, Management Analysis
and Services Office, CDC, pursuant to Public Law 92-463.
Matters for Discussion: The meeting will include the initial
review, discussion, and evaluation of applications received in
response to ``Conducting Public Health Research in Kenya, FOA GH15-
001''.
Contact Person for More Information: Hylan Shoob, Scientific
Review Officer, Center for Global Health (CGH) Science Office, CGH,
CDC, 1600 Clifton Road, NE., Mailstop D-69, Atlanta, Georgia 30033,
Telephone: (404) 639-4796.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining
to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention
and the Agency for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2015-05577 Filed 3-11-15; 8:45 am]
BILLING CODE 4163-18-P
